{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T16:51:50Z","timestamp":1787849510743,"version":"build-2784847793"},"reference-count":32,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005860","name":"Helsefonden","doi-asserted-by":"publisher","award":["20-B-0035"],"award-info":[{"award-number":["20-B-0035"]}],"id":[{"id":"10.13039\/501100005860","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007403","name":"Dagmar Marshalls Fond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007403","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004331","name":"Snedkermester Sophus Jacobsen og Hustru Astrid Jacobsens Fond","doi-asserted-by":"publisher","award":["2020-0379"],"award-info":[{"award-number":["2020-0379"]}],"id":[{"id":"10.13039\/501100004331","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004331","name":"Snedkermester Sophus Jacobsen og Hustru Astrid Jacobsens Fond","doi-asserted-by":"publisher","award":["J 167\/1"],"award-info":[{"award-number":["J 167\/1"]}],"id":[{"id":"10.13039\/501100004331","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.amjmed.2021.11.008","type":"journal-article","created":{"date-parts":[[2021,11,30]],"date-time":"2021-11-30T17:19:58Z","timestamp":1638292798000},"page":"595-602.e5","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran"],"prefix":"10.1016","volume":"135","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8196-2599","authenticated-orcid":false,"given":"Anders","family":"Holt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarl E.","family":"Strange","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter Vibe","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Blanche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina","family":"Nouhravesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3423-5495","authenticated-orcid":false,"given":"Mads Hashiba","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Schjerning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Schou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Torp-Pedersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-402X","authenticated-orcid":false,"given":"Gunnar H.","family":"Gislason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten Lock","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"McGettigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Lamberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.amjmed.2021.11.008_bib0001","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1093\/eurheartj\/ehy136","article-title":"The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation","volume":"39","author":"Steffel","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2021.11.008_bib0002","unstructured":"European Medicines Agency. European public assessment report, Eliquis. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/eliquis. Accessed June 22, 2021."},{"key":"10.1016\/j.amjmed.2021.11.008_bib0003","unstructured":"European Medicines Agency. European public assessment report, Pradaxa. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/pradaxa. Accessed June 22, 2021."},{"key":"10.1016\/j.amjmed.2021.11.008_bib0004","unstructured":"European Medicines Agency. European public assessment report, Xarelto. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/xarelto. Accessed June 22, 2021."},{"key":"10.1016\/j.amjmed.2021.11.008_bib0005","unstructured":"European Medicines Agency. European public assessment report, Lixiana. Available at: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/lixiana. Accessed June 23, 2021."},{"issue":"July","key":"10.1016\/j.amjmed.2021.11.008_bib0006","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.phrs.2018.07.016","article-title":"Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs)","volume":"135","author":"Gelosa","year":"2018","journal-title":"Pharmacol Res"},{"issue":"5","key":"10.1016\/j.amjmed.2021.11.008_bib0007","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/17425255.2019.1604686","article-title":"Pharmacokinetics and pharmacodynamics of oral anticoagulants used in atrial fibrillation","volume":"15","author":"Fawzy","year":"2019","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"10.1016\/j.amjmed.2021.11.008_bib0008","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ijantimicag.2013.07.004","article-title":"Outpatient systemic antimycotic and antifungal use in Europe: new outcome measure provides new insight","volume":"42","author":"Adriaenssens","year":"2013","journal-title":"Int J Antimicrob Agents"},{"issue":"13","key":"10.1016\/j.amjmed.2021.11.008_bib0009","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1001\/jama.2017.13883","article-title":"Association between use of non\u2013vitamin K oral anticoagulants with and without concurrent medications and risk of major bleeding in nonvalvular atrial fibrillation","volume":"318","author":"Chang","year":"2017","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.amjmed.2021.11.008_bib0010","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/bcp.12075","article-title":"Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects","volume":"76","author":"Mueck","year":"2013","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.amjmed.2021.11.008_bib0011","doi-asserted-by":"crossref","first-page":"e00647","DOI":"10.1002\/prp2.647","article-title":"Drug interactions with apixaban: a systematic review of the literature and an analysis of VigiBase, the World Health Organization database of spontaneous safety reports","volume":"8","author":"Fernandez","year":"2020","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"10.1016\/j.amjmed.2021.11.008_bib0012","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/201010581502400209","article-title":"Increased bleeding tendency from interaction between rivaroxaban and topical miconazole: case report","volume":"24","author":"Lee","year":"2015","journal-title":"Proc Singapore Healthc"},{"issue":"5","key":"10.1016\/j.amjmed.2021.11.008_bib0013","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1016\/j.amjmed.2020.10.018","article-title":"Antimycotic treatment of oral candidiasis in warfarin users","volume":"134","author":"Iversen","year":"2021","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.amjmed.2021.11.008_bib0014","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1365-2710.2010.01229.x","article-title":"Warfarin and miconazole oral gel interactions: analysis and therapy recommendations based on clinical data and a pharmacokinetic model","volume":"36","author":"Miki","year":"2011","journal-title":"J Clin Pharm Ther"},{"issue":"8","key":"10.1016\/j.amjmed.2021.11.008_bib0015","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10654-014-9930-3","article-title":"The Danish Civil Registration System as a tool in epidemiology","volume":"29","author":"Schmidt","year":"2014","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.amjmed.2021.11.008_bib0016","doi-asserted-by":"crossref","first-page":"449","DOI":"10.2147\/CLEP.S91125","article-title":"The Danish National Patient Registry: a review of content, data quality, and research potential","volume":"7","author":"Schmidt","year":"2015","journal-title":"Clin Epidemiol"},{"issue":"7 suppl","key":"10.1016\/j.amjmed.2021.11.008_bib0017","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1177\/1403494810394717","article-title":"The Danish National Prescription Registry","volume":"39","author":"Kildemoes","year":"2011","journal-title":"Scand J Public Health"},{"issue":"9","key":"10.1016\/j.amjmed.2021.11.008_bib0018","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1093\/eurheartj\/ehaa1058","article-title":"Effect of long-term beta-blocker treatment following myocardial infarction among stable, optimally treated patients without heart failure in the reperfusion era: a Danish, nationwide cohort study","volume":"42","author":"Holt","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.amjmed.2021.11.008_bib0019","doi-asserted-by":"crossref","unstructured":"Holt A, Blanche P, Zareini B, et al. Gastrointestinal bleeding risk following concomitant treatment with oral glucocorticoids in patients on non-vitamin K oral anticoagulants [online ahead of print]. Heart. 2021 Aug 13;heartjnl-2021-319503. doi:10.1136\/heartjnl-2021-319503","DOI":"10.1136\/heartjnl-2021-319503"},{"issue":"5","key":"10.1016\/j.amjmed.2021.11.008_bib0020","doi-asserted-by":"crossref","first-page":"574.e13","DOI":"10.1016\/j.amjmed.2017.11.046","article-title":"The HAS-BLED, ATRIA, and ORBIT bleeding scores in atrial fibrillation patients using non-vitamin K antagonist oral anticoagulants","volume":"131","author":"Lip","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.amjmed.2021.11.008_bib0021","doi-asserted-by":"crossref","first-page":"d124","DOI":"10.1136\/bmj.d124","article-title":"Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study","volume":"342","author":"Olesen","year":"2011","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.amjmed.2021.11.008_bib0022","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/rssc.12350","article-title":"The mean, variance and correlation for bivariate recurrent event data with a terminal event","volume":"68","author":"Scheike","year":"2019","journal-title":"J R Stat Soc Ser C Appl Stat"},{"issue":"2","key":"10.1016\/j.amjmed.2021.11.008_bib0023","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1093\/oxfordjournals.aje.a115853","article-title":"The case-crossover design: a method for studying transient effects on the risk of acute events","volume":"133","author":"Maclure","year":"1991","journal-title":"Am J Epidemiol"},{"issue":"6","key":"10.1016\/j.amjmed.2021.11.008_bib0024","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1002\/pds.5227","article-title":"Control yourself: ISPE-endorsed guidance in the application of self-controlled study designs in pharmacoepidemiology","volume":"30","author":"Cadarette","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.amjmed.2021.11.008_bib0025","unstructured":"R Core Team. R: a language and environment for statistical computing. Vienna, Austria; R Foundation for Statistical Computing. Available at: https:\/\/www.r-project.org\/. Accessed May 20, 2020."},{"issue":"3","key":"10.1016\/j.amjmed.2021.11.008_bib0026","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1097\/00001648-199505000-00010","article-title":"The case-time-control design","volume":"6","author":"Suissa","year":"1995","journal-title":"Epidemiology"},{"key":"10.1016\/j.amjmed.2021.11.008_bib0027","doi-asserted-by":"crossref","first-page":"185","DOI":"10.2147\/CLEP.S129879","article-title":"Confounding in observational studies based on large health care databases: problems and potential solutions - a primer for the clinician","volume":"9","author":"N\u00f8rgaard","year":"2017","journal-title":"Clin Epidemiol"},{"issue":"17","key":"10.1016\/j.amjmed.2021.11.008_bib0028","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the treatment of venous thromboembolism associated with cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2021.11.008_bib0029","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ejca.2021.02.026","article-title":"Effects of concomitant administration of anticancer agents and apixaban or dalteparin on recurrence and bleeding in patients with cancer-associated venous thromboembolism","volume":"148","author":"Verso","year":"2021","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.amjmed.2021.11.008_bib0030","article-title":"Causal analyses of existing databases: no power calculations required","author":"Hern\u00e1n","year":"2021","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.amjmed.2021.11.008_bib0031","unstructured":"Prescriber's digital reference. Available at: https:\/\/www.pdr.net\/. Accessed June 7, 2021."},{"issue":"11","key":"10.1016\/j.amjmed.2021.11.008_bib0032","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1001\/jamainternmed.2018.5766","article-title":"Studying drug safety in the real world","volume":"178","author":"Zipursky","year":"2018","journal-title":"JAMA Intern Med"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934321007932?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934321007932?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T01:00:54Z","timestamp":1778634054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934321007932"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":32,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0002934321007932"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2021.11.008","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bleeding Risk Following Systemic Fluconazole or Topical Azoles in Patients with Atrial Fibrillation on Apixaban, Rivaroxaban, or Dabigatran","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2021.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}